Literature DB >> 22024415

Impact of molecular mimicry on the clinical course and outcome of sepsis syndrome.

Katalin Kristóf1, Krisztina Madách, Noémi Sándor, Zsolt Iványi, András Király, Anna Erdei, Eszter Tulassay, János Gál, Zsuzsa Bajtay.   

Abstract

We investigated the impact of molecular mimicry between pathogenic microbes and their antigenic surrounding on the clinical course and outcome of pneumonia induced sepsis. Using mathematical prediction, we estimated the mimicry tendency of the identified pathogenic flora of patients with the human proteome as well as intestinal microbes. Since gut bacteria become invasive and hostile in critical illness, mimicry between these organisms and the infectious flora is expected to be rather hyperinflammatory type, in contrast to the expectedly tolerogenic self versus pathogen cross-reactions. Differential effects of these two kinds of cross-reactions were studied. The predicted similarity of the identified pathogenic flora and intestinal microbes was higher in non-survivor patients compared to survivors (P=0.019). Higher values of "pathogen versus intestinal flora/pathogen versus human proteome" mimicry ratios (inflammatory quotients) were associated with mortality at a higher extent of significance (P<0.01), and correlated with admission APACHE II disease severity scores (R=0.311; P=0.017). We also found a correlation between the previously reported sepsis mortality rates by causative agent and the corresponding inflammatory quotients of these pathogens (R=0.738; P<0.05). Gram negative species showed higher similarity to intestinal bacteria and reached higher inflammatory quotients compared to Gram positives (P=0.01 and P<0.01, respectively). The disadvantageous effect of "pathogen versus intestinal flora" mimicry - presumably due to the extension of inflammation from the infectious focus to the already injured gut - is in accordance with the gut-lymph hypothesis, assessing that the destruction of the intestinal symbiosis culminates in the formation of damageous gut origin lymph. Our results raise the idea that molecular mimicry between pathogenic microbes and their antigenic surrounding might be a contributing factor behind the clinically and experimentally observed differences in microbiologically distinct forms of sepsis syndrome.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 22024415     DOI: 10.1016/j.molimm.2011.09.023

Source DB:  PubMed          Journal:  Mol Immunol        ISSN: 0161-5890            Impact factor:   4.407


  5 in total

1.  Loss of enteral nutrition in a mouse model results in intestinal epithelial barrier dysfunction.

Authors:  Yongjia Feng; Matthew W Ralls; Weidong Xiao; Eiichi Miyasaka; Richard S Herman; Daniel H Teitelbaum
Journal:  Ann N Y Acad Sci       Date:  2012-07       Impact factor: 5.691

2.  Parenteral nutrition increases susceptibility of ileum to invasion by E coli.

Authors:  Joseph F Pierre; Aaron F Heneghan; Jennifer M Meudt; Michael P Shea; Christian G Krueger; Jess D Reed; Kenneth A Kudsk; Dhanansayan Shanmuganayagam
Journal:  J Surg Res       Date:  2013-02-24       Impact factor: 2.192

3.  The impact of obesity on sepsis mortality: a retrospective review.

Authors:  Ethan F Kuperman; John W Showalter; Erik B Lehman; Amy E Leib; Jennifer L Kraschnewski
Journal:  BMC Infect Dis       Date:  2013-08-16       Impact factor: 3.090

Review 4.  Intestinal epithelial cell apoptosis and loss of barrier function in the setting of altered microbiota with enteral nutrient deprivation.

Authors:  Farokh R Demehri; Meredith Barrett; Matthew W Ralls; Eiichi A Miyasaka; Yongjia Feng; Daniel H Teitelbaum
Journal:  Front Cell Infect Microbiol       Date:  2013-12-23       Impact factor: 5.293

5.  Diet-dependent, microbiota-independent regulation of IL-10-producing lamina propria macrophages in the small intestine.

Authors:  Takanori Ochi; Yongjia Feng; Sho Kitamoto; Hiroko Nagao-Kitamoto; Peter Kuffa; Koji Atarashi; Kenya Honda; Daniel H Teitelbaum; Nobuhiko Kamada
Journal:  Sci Rep       Date:  2016-06-15       Impact factor: 4.379

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.